Horizon Inks $660M Deal For Specialty Drugmaker

Law360, New York (March 19, 2014, 1:11 PM EDT) -- Horizon Pharma Inc. said Wednesday it would pick up Ireland’s Vidara Therapeutics International Ltd. in a cash-and-stock transaction worth $660 million, expanding the Illinois-based pharmaceutical company’s portfolio of medications marketed in the U.S. and Europe.

Under the terms of the deal, Horizon Pharma will acquire Vidara through a reverse merger, according to a statement. Shareholders of Horizon will hold roughly 74 percent of the surviving company, Horizon Pharma PLC, while shareholders of Vidara will hold about 26 percent and receive $200 million in cash. Horizon Pharma...
To view the full article, register now.